Art. -Nr.: HY-108877

Cefepime hydrochloride

(Synonyms: BMY-28142 hydrochloride)

16 Cited Publications

Kundenbewertung

Based on 16 publication(s) in Google Scholar

Cefepime (BMY-28142) hydrochloride is a broad-spectrum, blood-brain barrier-permeable cephalosporin antibiotic with hPON1 inhibitory activity, with an IC₅₀ of 21.115 mM and a K_i of 35.092 mM. Cefepime hydrochloride inhibits hPON1 via a non-competitive mechanism and blocks GABA_A receptors. Cefepime hydrochloride penetrates the outer membrane of Gram-negative bacteria, inhibits the growth of Gram-positive and Gram-negative bacteria, and does not induce the production of β-lactamase.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 107648-80-6
Formel: C₁₉H₂₆Cl₂N₆O₅S₂
Molecular Weight:553.48

Speicherung:

-20°C, stored under nitrogen, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Data Sheet (280 KB)

Cefepime hydrochloride Chemical Structure

CAS. Nr.: 107648-80-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (16)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

In Vitro

Cefepime (18 h) hydrochloride potently inhibits most isolates of Gram-negative aerobic bacteria. Among these pathogens, the MIC₉₀ value is ≤1 mg/L for most Enterobacteriaceae, 16 mg/L for Pseudomonas aeruginosa, and ≤0.12 mg/L for Haemophilus influenzae, Neisseria gonorrhoeae and Branhamella catarrhalis^[4].
Cefepime (18-48 h) hydrochloride inhibits Gram-positive bacterial isolates, with an MIC₉₀ value of ≤ 4 mg/L against staphylococci and an MIC₉₀ value of ≤ 0.25 mg/L against most streptococci, but shows limited activity against Enterococcus faecalis, Listeria monocytogenes and Bacteroides species^[4].
Cefepime hydrochloride exhibits stable in vitro activity across different culture media, pH values, and inoculum sizes. For most isolates, the difference between its MIC and MBC values is extremely small, but the MBC values of Pseudomonas aeruginosa and Staphylococcus aureus in human serum are higher^[4].
Cefepime (2-8×MIC; 2-24 h) hydrochloride exhibits concentration-dependent bactericidal activity against Enterobacter cloacae (with the strongest activity and no regrowth observed at 8×MIC), sustained bactericidal activity against Pseudomonas aeruginosa, but only limited transient activity against Methicillin (HY-121544)-resistant Staphylococcus aureus^[4].
Cefepime (1 mM) hydrochloride exhibits high stability against almost all tested plasmid-mediated and chromosome-mediated bacterial β-lactamases, and is only slightly hydrolyzed by the PSE-2 enzyme^[4].
Cefepime hydrochloride is a weak inhibitor of most bacterial β-lactamases, exhibiting only weak activity against Proteus vulgaris Ic enzyme and Pseudomonas aeruginosa Id enzyme, with an IC₅₀ value of > 400 mg/L against the key clinical β-lactamases TEM-1 and P99^[4].
Cefepime hydrochloride exhibited only marginal differences in MIC values among Escherichia colipermeability mutants, whereas an 8-fold difference was observed among Pseudomonas aeruginosapermeability mutants, indicating that its ability to enhance bacterial cell wall penetration is limited^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cefepime hydrochloride induces bacterial stasis in a neutropenic murine thigh infection model infected with Enterobacteriaceae and Klebsiella pneumoniae, under the condition that the unbound drug concentration remains above the MIC for 0-37.7% of the dosing interval^[2].
Cefepime (250-500 mg/kg; intravenous bolus) hydrochloride does not increase the susceptibility to pentylenetetrazol (PTZ)-induced convulsions in normal male ICR mice^[3].
Cefepime (250-500 mg/kg; intravenous bolus) hydrochloride significantly increases the average seizure grade to 3.3 in the low-current electroshock-induced seizure model of normal male ICR mice, while the 250 mg/kg dose increases the average seizure grade to 2.0^[3].
Cefepime (500 mg/kg; intravenous bolus) hydrochloride induces convulsions in 2 out of 3 normal male ICR mice, and elicits electroencephalogram spike waves in the parietal cortex of 1 mouse following low-current electroshock stimulation^[3].
Cefepime (500 mg/kg; intravenous bolus) hydrochloride significantly increases the average seizure grade induced by low-current electroconvulsive shock to 4.0 in cornea-kindled male ICR mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 107648-80-6
Appearance Solid
Molecular Weight 553.48
Formel C₁₉H₂₆Cl₂N₆O₅S₂
Color White to off-white
SMILES

OC(C(N(C1=O)[C@@](SC2)([H])[C@@H]1NC(/C(C3=CSC(N)=N3)=N\OC)=O)=C2C[N+]4(CCCC4)C)=O.[Cl-].Cl
Synonyms

BMY-28142 hydrochloride
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

-20°C, stored under nitrogen, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Publications (16)

All Microbiological Assay

Sort by:

Journal Impact Factor

J Exp Med

Antibiotic use in early life impairs MAIT cell-mediated immunity in adulthood. [Abstract]

2026 Mar 2;223(3):e20241287. PMID: 41400657
Emerg Microbes Infect

AMXT-1501 targets membrane phospholipids against Gram-positive and -negative multidrug-resistant bacteria. [Abstract]

2024 Dec;13(1):2321981. PMID: 38422452
Pharmaceutics

Stability Studies of Antipseudomonal Beta Lactam Agents for Outpatient Therapy. [Abstract]

2023 Nov 30;15(12):2705. PMID: 38140046
Virulence

Antibacterial efficacy and mechanism of the novel antimicrobial peptide lachnospirin-1 against Acinetobacter baumannii. [Abstract]

2026 Dec 31;17(1):2646808. PMID: 41838520
Molecules

Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]

2025 Mar 9;30(6):1224. PMID: 40142001
Int J Antimicrob Agents

Elucidating adaptive compensatory tigecycline resistance mechanisms of RamA, RarA and SoxS in Klebsiella pneumoniae. [Abstract]

2025 Oct;66(4):107551. PMID: 40499596
Antimicrob Agents Chemother

Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO. [Abstract]

2025 Jun 4;69(6):e0010225. PMID: 40372025
J Antimicrob Chemother

Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study. [Abstract]

2026 Feb 2;81(3):dkag034. PMID: 41648989

Cefepime hydrochloride purchased from MedChemExpress. Usage Cited in: J Antimicrob Chemother. 2026 Feb 2;81(3):dkag034. [Abstract]

Activities of new β-lactam/β-lactamase inhibitors (Cefepime, et al.) against AmpC-hyperproducing E. cloacae complex and Klebsiella aerogenes were evaluated.
J Antimicrob Chemother

Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]

2025 Nov 5:dkaf408. PMID: 41206063
J Glob Antimicrob Resist

Genomic characterization of carbapenem-resistant Pseudomonas aeruginosa from ICU admission screening in Hanoi, Vietnam, 2023. [Abstract]

2025 Jul 7:44:265-271. PMID: 40633763
Infect Genet Evol

Polymyxin B combined with amikacin delays the resistance of Klebsiella pneumoniae to polymyxin B by modulating the expression of NlpE. [Abstract]

2025 Sep:133:105780. PMID: 40480594

Cefepime hydrochloride purchased from MedChemExpress. Usage Cited in: Infect Genet Evol. 2025 Sep:133:105780. [Abstract]

Antibiotic sensitivity of K. pneumoniae Kp81 and its derivatives.
Vet Microbiol

Discovery of the tigecycline resistance gene cluster tmexCD3-toprJ1 in Pasteurella multocida strains isolated from pigs in China. [Abstract]

2024 May:292:110046. PMID: 38471428

Cefepime hydrochloride purchased from MedChemExpress. Usage Cited in: Vet Microbiol. 2024 May:292:110046. [Abstract]

MICs for 16 antimicrobial agents against 381 strains of P. multocida from pigs.
^a AMP: ampicillin, AMX: amoxicillin, CEF: ceftiofur, CIP: ciprofloxacin, COL: colistin, CPM: Cefepime, DOX: doxycycline, ENR: enrofloxacin, ERY: erythromycin, FFC: florfenicol, GEN: gentamicin, IPM: imipenem, SPT: spectinomycin, TET: tetracycline, TGC: tigecycline, TIL: tilmicosin.
^b NA: breakpoint not available.
^c veterinary-specific breakpoints applicable to porcine P. multocida from CLSI VET01S ED7:2024; light grey shading – susceptible, dark grey shading – intermediate, black shading – resistant.
J Antibiot (Tokyo)

Impact of short chain fatty acids (SCFAs) on antimicrobial activity of new β-lactam/β-lactamase inhibitor combinations and on virulence of Escherichia coli isolates. [Abstract]

2023 Apr;76(4):225-235. PMID: 36726014

Cefepime hydrochloride purchased from MedChemExpress. Usage Cited in: J Antibiot (Tokyo). 2023 Apr;76(4):225-235. [Abstract]

Susceptibility patterns of E. coli isolates (n = 140) towards different β-Lactams singly and in combination with β-Lactamase inhibitors (CFP Cefoperazone, CAZ Ceftazidime, FEP Cefepime). The results showed that cephalosporins were effective against E. coli isolates at the following rates: cefoperazone (52.9%), ceftazidime (43.5%), and Cefepime (32.1%).
Res Sq

2026 Mar 9.
Patent

US20240209004A1.
bioRxiv

2024 May 10.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Türkeş C, et al. Human serum paraoxonase-1 (hPON1): in vitro inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate, cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium. J Enzyme Inhib Med Chem. 2015;30(4):622-628. [Content Brief]

[2]. Pais GM, et al. Clinical Pharmacokinetics and Pharmacodynamics of Cefepime. Clin Pharmacokinet. 2022;61(7):929-953. [Content Brief]

[3]. Tanaka A, et al. Convulsive liability of cefepime and meropenem in normal and corneal kindled mice. Antimicrob Agents Chemother. 2014;58(8):4380-4383. [Content Brief]

[4]. Neu HC, et al. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin. J Antimicrob Chemother. 1986;17(4):441-452. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Cefepime hydrochloride

16 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Cefepime hydrochloride

Publications Citing Use of MedChemExpress (MCE) Cefepime hydrochloride

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (16)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Cefepime hydrochloride Related Classifications

HY-108877 Related Classifications